Compare LAW & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | PROK |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.6M | 229.9M |
| IPO Year | 2021 | 2021 |
| Metric | LAW | PROK |
|---|---|---|
| Price | $3.79 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $8.00 | $7.40 |
| AVG Volume (30 Days) | 325.7K | ★ 752.2K |
| Earning Date | 05-06-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,849,000.00 | $893,000.00 |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.29 | ★ 1075.00 |
| 52 Week Low | $2.45 | $0.46 |
| 52 Week High | $9.11 | $7.13 |
| Indicator | LAW | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 38.67 |
| Support Level | $2.45 | $1.71 |
| Resistance Level | $4.63 | $2.58 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 16.35 | 24.69 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.